Note 13 – Sales by region2012 2011France (including overseas department and territories) 123,445 108,958Europe excluding France 104,316 105,492Europe including France 227,761 214,450Asia 27,271 26,031Latin America 24,188 26,083North America 7,115 9,798O<strong>the</strong>r countries 14,360 14,643Total 300,695 291,005Note 14 – Operating grantsIn December 2008, <strong>the</strong> request for aid submitted to OSEO innovation agency for <strong>the</strong> Franco-Germanresearch project, Iseult, was approved by <strong>the</strong> European commission. The aid agreement provides forfinancing for one half of <strong>the</strong> expenses incurred including 39% in <strong>the</strong> form of repayable advances and 61% in<strong>the</strong> form of grants.At 31 December 2012, <strong>the</strong> following items were recognised in connection with this aid agreement:In <strong>the</strong> balance sheet:- €2.3 million in grants received prior to <strong>the</strong> signature of <strong>the</strong> agreement in December 2008 andrecognised under "O<strong>the</strong>r current financial liabilities";- €1.8 million in repayable advances received from 2008 to 2011 and recognised under "Non-currentfinancial liabilities".- €1.4 million in grants receivable for research expenditures incurred by <strong>Guerbet</strong> from 1 July 2011 to30 June 2012. These grants are recognised under "O<strong>the</strong>r current financial assets".In <strong>the</strong> income statement:- €1.4 million recognised under "O<strong>the</strong>r revenue from ordinary activities" for this grant receivable.A €1.6 million repayable advance to be received in 2013 by <strong>Guerbet</strong> for research expenditures incurredfrom July 2011 to June 2012. This item was not recognised in <strong>the</strong> financial statements at 31 December2012.In 2011, <strong>Guerbet</strong> received and recognised financing of €2.5 million including €2.4 million in grants and €0.1million in repayable advances for research expenditures incurred by <strong>Guerbet</strong> from July 2010 to June 2011.The amount of contingent income that remains to be received for research expenditures incurred in <strong>the</strong>2012 second half but not yet approved by Oseo at <strong>the</strong> end of <strong>the</strong> reporting period and not recognised in <strong>the</strong>income statement would amount to €503,000 in grants. To this, €325,000 in repayable advances should beadded.An amendment is in <strong>the</strong> process of being executed with Oseo that provides for a two-year extension of <strong>the</strong>term of <strong>the</strong> project and a modification of <strong>the</strong> terms for financial returns in <strong>the</strong> eventuality a product is put on<strong>the</strong> market on completion of <strong>the</strong> project.Note 15 – O<strong>the</strong>r incomeAn insurance payment of €3.3 million was paid for material damage and business interruption losses for <strong>the</strong>claim of November 2011 involving our Lanester site.127
Note 16 – Staff costs2012 2011Salaries and wages (46,608) (44,422)Social security charges (21,065) (20,157)Total (67,673) (64,579)Note 17 – Net financial income/(expense)2012 2011Dividends - 3,010Interest income/(expense) (879) (1,306)Currency gains/(losses) (454) (3,329)Net provisions on investments 362 (3,994)Cancellation of debt - -O<strong>the</strong>r 128 170Total (843) (5,449)Note 18 – Exceptional profit (loss)2012 2011Waiver of Medex debt 1 (4,553) -Net charges on regulated provisions (4,950) (6,164)Net gains from <strong>the</strong> retirement of assets (1,787) (469)Indemnity received for breach of contract 1,195 -O<strong>the</strong>r 196 (330)Total (9,899) (6,963)Note 19 – Income taxSince 1988, <strong>the</strong> Group has opted for filing under <strong>the</strong> French tax-sharing provisions for tax groups. The taxgroup includes <strong>Guerbet</strong> and Simafex.The tax charges are recorded by <strong>the</strong> consolidated companies (subsidiaries and parent company) as in <strong>the</strong>absence of tax-sharing provisions. Savings achieved by <strong>the</strong> Group unrelated to losses (adjustments relatedto certain intercompany transactions) are passed on to <strong>the</strong> parent company and recorded by <strong>the</strong> latter asincome. Research and tax credits are re-allocated to <strong>the</strong> companies that produced <strong>the</strong>m. Tax savingsresulting from tax losses of subsidiaries are also re-allocated in <strong>the</strong>ir favour by applying <strong>the</strong>m to future taxearnings.The total tax profit at <strong>the</strong> standard rate of <strong>the</strong> French tax group for fiscal 2012 was €14.34 million. The taxcharge of <strong>the</strong> French tax group totalled €1.74 million after <strong>the</strong> application of tax credits including a researchtax credit of €3.37 million. Because <strong>the</strong> tax charge owed by <strong>the</strong> French tax group is lower than <strong>the</strong> amountof tax credits, tax receivable of €4.23 million for research tax credits is recorded under "O<strong>the</strong>r tradereceivables".1 This waiver is accompanied by a financial recovery clause.128